1. Search Result
Search Result
Results for "

cancer imaging

" in MedChemExpress (MCE) Product Catalog:

54

Inhibitors & Agonists

10

Fluorescent Dye

3

Biochemical Assay Reagents

14

Peptides

1

Inhibitory Antibodies

5

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-153550

    Radionuclide-Drug Conjugates (RDCs) PSMA Others
    PSMA-1007 is a prostate-specific membrane antigen (PSMA) ligand. 18F-labeled PSMA-1007 can be used as a PET tracer for prostate cancer imaging .
    PSMA-1007
  • HY-D1063

    Fluorescent Dye Cancer
    IR780 is a prototypic NIR heptamethine cyanine agent, with a high molar extinction coefficient. The maximum excitation wavelength of IR780 was 777-780 nm, and the maximum emission wavelength was 798-823 nm. IR780 can be used in cancer PTT/PDT and imaging .
    IR-780
  • HY-148761

    PSMA Cancer
    PSMA I&T is an effective inhibitor of prostate-specific membrane antigen (PSMA). PSMA I&T can be used for SPECT/CT imaging and radionuclide studies in triple-negative breast cancer and prostate cancer (PCa) .
    PSMA I&T
  • HY-137331
    FAPI-46
    1 Publications Verification

    FAP Cancer
    FAPI-46 is a quinoline-based fibroblast activation protein (FAP)-targeted radiotracer. FAPI-46 has higher tumor uptake and prolonged tumor accumulation. FAPI-46 can be used for tumor imaging of a multitude of different cancers .
    FAPI-46
  • HY-P5292A

    Radionuclide-Drug Conjugates (RDCs) PSMA Cancer
    HYNIC-iPSMA TFA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA TFA has excellent specificity and sensitivity .
    HYNIC-iPSMA TFA
  • HY-141511
    Coppersensor 1
    5+ Cited Publications

    Fluorescent Dye Neurological Disease Cancer
    Coppersensor-1 (CS1) is a membrane-permeable fluorescent dye. Coppersensor-1 has a picomolar affinity for Cu + with high selectivity over competing cellular metalions. Coppersensor-1 as a probe, can selective and sensitive detection of copper(I) ions (Cu +) in biological samples, including live cells. Coppersensor-1 can be used for the research of imaging of severe diseases such as cancer, cardiovascular disorders and neurogenerative diseases .
    Coppersensor 1
  • HY-163539

    LUM015

    Others Cancer
    Pegulicianine acetate (LUM015) is a potent fluorescent imaging agent can be used to the detection of cancer tissue .
    Pegulicianine acetate
  • HY-158251

    Others Cancer
    BIBD-300 is a PARP-1 imaging agent with high affinity for PARP-1. BIBD-300 can accurately localize C6 and U87MG tumors, which can be used for research in the diagnosis of breast cancer, prostate cancer, glioma, and liver cancer .
    BIBD-300
  • HY-P5292

    Radionuclide-Drug Conjugates (RDCs) PSMA Cancer
    HYNIC-iPSMA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA has excellent specificity and sensitivity .
    HYNIC-iPSMA
  • HY-D2315

    Fluorescent Dye Cancer
    Probe-Cys is a water-soluble and selective near-infrared fluorescent probe for Cys (λex= 680 nm, λem=710 nm) that is not interfered by Hcy, GSH, and HS-. Probe-Cys can react with the stimulant 1,4-dimercaptothreitol (DTT) and the inhibitor N-ethylmaleimide (NEM) in HepG2 cells and zebrafish for the detection of endogenous Cys. Probe-Cys can also be used for imaging Cys in Arabidopsis thaliana. Probe-Cys provides a method for cancer diagnosis and exploration of plant sulfur metabolism .
    Probe-Cys
  • HY-P10744

    Radionuclide-Drug Conjugates (RDCs) PSMA Cancer
    BQ7859 is a probe targeting PSMA that contains a NOTA chelator and demonstrates excellent imaging performance. BQ7859 can be labeled with various radionuclides, such as 68Ga, 18F, 55Co, and 111In. In a mouse prostate cancer xenograft model, BQ7859 (labeled with 111In) efficiently accumulates in tumor regions in a PSMA-dependent manner and provides high-contrast tumor imaging. BQ7859 shows potential for research in prostate cancer imaging, particularly in positron emission tomography (PET) and single-photon emission computed tomography (SPECT) .
    BQ7859
  • HY-P5287

    Integrin Cancer
    cRGDfK-thioacetyl ester is a bioactive polypeptide molecule. cRGDfK peptide has a selective affinity for integrins. cRGDfK peptide can modify NIR fluorescent probes for cancer targeting imaging .
    cRGDfK-thioacetyl ester
  • HY-P5287A

    Integrin Cancer
    cRGDfK-thioacetyl ester TFA is a bioactive polypeptide molecule. cRGDfK peptide has a selective affinity for integrins. cRGDfK peptide can modify NIR fluorescent probes for cancer targeting imaging .
    cRGDfK-thioacetyl ester TFA
  • HY-135793

    Others Cancer
    Macropa-NH2 diester is a compound can be used for imaging during the investigation of cancer. Macropa-NH2 diester is compound 210 extracted from patent WO2018187631 .
    Macropa-NH2 diester
  • HY-154844

    Others Cancer
    FAP Ligand 1 (FL), a high-affinity FAP small-molecule ligand, is used to target attached drugs to FAP-expressing fibroblasts and can be used in radiation imaging studies of targeted cancers .
    FAP Ligand 1
  • HY-164725

    Radionuclide-Drug Conjugates (RDCs) FAP Cancer
    FAPI-mFS is an irreversible fibroblast activation protein (FAP) inhibitor, that enhances the uptake and retention time in cancer cells through its covalent binding property for FAP. FAPI-mFS can be used for cancer imaging the therapy, when labeled with radioactive 68Ga or 177Lu .
    FAPI-mFS
  • HY-160063

    Fluorescent Dye DNA Alkylator/Crosslinker Cancer
    SW1 aptamer sodium is a high-affinity DNA aptamer (Kd: 123.62 nM) that targets liver cancer SMMC-7721 cells and targets intracellular components within the nucleus. SW1 aptamer sodium can also identify various other types of cancer cells and tissues, serving as an effective molecular probe for clinical cancer diagnosis .
    SW1 aptamer sodium
  • HY-128643
    FAPI-4
    Maximum Cited Publications
    22 Publications Verification

    FAP Cancer
    FAPI-4 is a potent fibroblast activation protein (FAP) inhibitor for the targeting FAP. FAPI-4 can be used in cancer research. 68Ga-FAPI-4 PET/CT is a promising new diagnostic method for imaging various kinds of cancer, with good tumor-to-background contrast ratios .
    FAPI-4
  • HY-149869

    PSMA Cancer
    PSMA-IN-3 (compound 17) is a novel high-affinity PSMA inhibitor with an IC50 value of 13 nM. PSMA-IN-3 is suitable for developing an 18F-labeled radioligand for PET imaging of PSMA in prostate cancer .
    PSMA-IN-3
  • HY-141637

    2-Fluoro-2-deoxy-D-glucose; 2-Deoxy-2-fluoro-D-glucopyranose

    Biochemical Assay Reagents Others
    2-Deoxy-2-fluoro-D-glucose, a radiolabeled glucose analog, is commonly used in medical imaging techniques such as positron emission tomography (PET) scans. FDG has unique chemical properties that allow it to be taken up by cells that actively metabolize glucose, such as cancer cells or inflamed tissue. Once absorbed, FDG emits positrons that can be detected in 2-Deoxy-2-fluoro-D-glucose scans, producing images that highlight areas of high metabolic activity in the body. This makes it a useful tool for diagnosing and monitoring a variety of diseases, including cancer and neurological disorders.
    2-Deoxy-2-fluoro-D-glucose
  • HY-164475

    PARP Cancer
    PARP1-IN-29 is an orally active PARP-1 inhibitor with an IC50 value of 6.3 nM. PARP1-IN-29, after being labeled with [18F], can be used for positron emission tomography (PET) imaging, specifically targeting PARP-1 in tumors. PARP1-IN-29 is applicable in the fields of oncology and imaging research, particularly for detecting PARP-1 activity in cancer .
    PARP1-IN-29
  • HY-150970

    Pyroptosis Cancer
    ICy-OH, an iodinated photosensitizer, is an effective anticancer agent. ICy-OH can be used not only for deep tissue imagingex=640 nm,λem=690-740 nm) but also to selectively induce cell death in pancreatic cancer cells via cell pyroptosis pathway .
    ICy-OH
  • HY-D1876

    Fluorescent Dye Cancer
    ZY-2 is a specific fluorescent probe for pyruvate kinase M2 (PKM2). ZY-2 can image in PKM2-positive cells in a time- and concentration-dependent manner. ZY-2 can be used for the detection of cancer cells .
    ZY-2
  • HY-155486

    Fluorescent Dye Cancer
    HCy-AAN-Bio is a tumor-targeted hemicyanine (HCy) probe for Fluorescent/photoacoustic (FL/PA) imaging of legumain in vivo. Legumain can specifically cleave HCy-AAN-Bio with the generation of FL/PA signal. HCy-AAN-Bio is a powerful tool for early diagnosis of associated cancer .
    HCy-AAN-Bio
  • HY-19997

    TATM

    Biochemical Assay Reagents Cancer
    Mannose triflate is a glucose analog. Mannose triflate is a precursor for 18F-FDG synthesis for PET applications. Mannose triflate binds to 18F via SN2 nucleophilic substitution reaction. Mannose triflate can be used for an imaging technique in detection of cancer .
    Mannose triflate
  • HY-P5290

    Radionuclide-Drug Conjugates (RDCs) PSMA Cancer
    HYNIC-PSMA is a ligand for molecular imaging of tumors. Hynic-psma consists of two components: HYNIC (6-hydrazinonicotinamide) and PSMA (Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules, such as 188Re-HYNIC-PSMA. PSMA is a membrane antigen that is specifically expressed on the surface of prostate cancer cells. HYNIC-PSMA can be used in prostate cancer research .
    HYNIC-PSMA
  • HY-D1456

    Pyruvate Kinase Cancer
    TEPC466 is a novel TEPP-46-based aggregation-induced emission (AIE) probe. TEPC466 shows a high degree of selectivity and sensitivity for the detection of PKM2 protein via the AIE effect. EPC466 can be used for the detection of PKM2. TEPC466 is successfully applied in imaging the PKM2 protein in colorectal cancer cells with low toxicity. TEPC466 is a useful tool for cancer diagnosis and research .
    TEPC466
  • HY-D1275

    Fluorescent Dye Others
    CAY10731 (compound 3) is a highly selective fluorescent probe for detection of hydrogen sulfide (H2S). CAY10731 is used to monitor exo- and endogenous H2S in both cancer and normal cells. CAY10731 is applied for imaging of H2S in living tissues at variable depths and in nematodes .
    CAY10731
  • HY-147865

    Galectin Apoptosis Cancer
    Apoptosis inducer 8 (Compound 7c) is a galectin-1 (gal-1) mediated apoptosis-inducing agent against global major leading lung cancer burden. Apoptosis inducer 8 significantly reduced the gal-1 protein level. Apoptosis inducer 8 is also a PET imaging agent .
    Apoptosis inducer 8
  • HY-124473

    Naphthafluorescein

    HIF/HIF Prolyl-Hydroxylase Cancer
    Naphthofluorescein inhibits the interaction between HIF-1 and Mint3. Naphthofluorescein suppresses Mint3-dependent HIF-1 activity and glycolysis in cancer cells and macrophages without cytotoxicity in vitro and adverse effect in vivo . Naphthofluorescein is also a fluorescent pH-sensitive probe that can be used for functional Cerenkov imaging .
    Naphthofluorescein
  • HY-125399

    HBED-CC-PSMA

    PSMA Radionuclide-Drug Conjugates (RDCs) Cancer
    PSMA-11 is a small molecule ligand that targets prostate-specific membrane antigen (PSMA) and has the ability to inhibit PSMA activity. PSMA-11 can be used to synthesize 68Ga-PSMA-11, a positron emission tomography (PET) tracer that can be used to image advanced prostate cancer .
    PSMA-11
  • HY-D2285

    Fluorescent Dye Cancer
    MOR-CES2 is a near-infrared fluorescent probe (Ex= 630 nm, Em=735 nm) capable of identifying cancer cells and tissues, as well as exhibiting a sensitive response to inflammation. MOR-CES2 holds potential as an efficient imaging tool in assisting surgical resection of CES2-related tumors .
    MOR-CES2
  • HY-P10743

    Radionuclide-Drug Conjugates (RDCs) PSMA Cancer
    BQ7876 is a probe targeting prostate-specific membrane antigen (PSMA) that contains a DOTA chelator. BQ7876, after being radiolabeled with radionuclide (177Lu), functions in both radionuclide imaging and tumor cell destruction by specifically binding to PSMA. BQ7876 shows potential for research in the field of metastatic castration-resistant prostate cancer (mCRPC) .
    BQ7876
  • HY-139401

    FAP Cancer
    FAPI-34 is a fibroblast-activating protein (FAP) inhibitor with favorable pharmacokinetic and biochemical properties. (patent WO2019154886A1).
    FAPI-34
  • HY-D1716

    Fluorescent Dye Cancer
    S0456 is a near-infrared (NIR) fluorescent dye that can be used for synthesize Pafolacianine (HY-139579). S0456 binds to the folate receptor (FR). S0456 can be used as a tumor-specific optical imaging agent. The excitation wavelength is 788 nM and emission wavelength is 800 nM .
    S0456
  • HY-D2334

    Radionuclide-Drug Conjugates (RDCs) HSP Cancer
    AlF-NOTA-c-d-VAP is a peptide positron emission tomography (PET) probe that used for targeted tumor imaging of GRP78. AlF-NOTA-c-d-VAP demonstrates high stability in vitro and in vivo .
    AlF-NOTA-c-d-VAP
  • HY-P10292

    Radionuclide-Drug Conjugates (RDCs) Interleukin Related Cancer
    NOTA-Pep-1L specifically targets the IL13RA2 receptor for tumor imaging .
    NOTA-Pep-1L
  • HY-W130177

    Biochemical Assay Reagents Cancer
    Iodocholine iodide is a non-toxic, metabolizable "green" catalyst that can catalyze the free radical polymerization of functional polymers. Iodocholine iodide is also the non-radioactive iodide of Carbon-11 choline. C-11 Choline can be used in PET imaging and non-informative bone scintigraphy, CT or MRI to monitor various types of cancer .
    Iodocholine iodide
  • HY-128642

    FAP Cancer
    FAPI-2 is a type of small molecule fibroblast activation protein inhibitor (FAPI) that targets the fibroblast activation protein (FAP) and has an inhibitory effect. This specific targeting ability makes FAPI-2 an effective tumor imaging agent, which can be used in cancer research. FAPI-2 can be used to synthesize 68Ga-FAPI-2 (a PET tracer) .
    FAPI-2
  • HY-160045

    Cholecystokinin Receptor Cancer
    AP1153 aptamer sodium is a DNA aptamer that specifically binds to the cholecystokinin receptor CCKBR (Kd: ~15 pM), but does not activate CCKBR-related signaling pathways. AP1153 aptamer sodium is internalized by pancreatic ductal adenocarcinoma (PDAC) cells in a receptor-mediated manner. AP1153 aptamer sodium can bioconjugate to the surface of fluorescent nanoparticles to facilitate nanoparticle delivery to PDAC tumors in vivo .
    AP1153 aptamer sodium
  • HY-128642A

    FAP Cancer
    FAPI-2 TFA is a type of small molecule fibroblast activation protein inhibitor (FAPI) that targets the fibroblast activation protein (FAP) and has an inhibitory effect. This specific targeting ability makes FAPI-2 TFA an effective tumor imaging agent, which can be used in cancer research. FAPI-2 TFA can be used to synthesize 68Ga-FAPI-2 (a PET tracer) .
    FAPI-2 TFA
  • HY-160062

    Mucin Cancer
    S2.2 aptamer sodium is a nucleic acid aptamer targeting the mucin MUC1 and can be used for targeted imaging of MCF-7 cancer cells. S2.2 aptamer sodium was labeled with Cy5, and when fluorescent silicon nanodots (SiND) were present, the fluorescence was quenched; when MUC1 was also present, the fluorescence was restored. S2.2 aptamer sodium detects MUC1 with a linear range of 3.33-250 nM .
    S2.2 aptamer sodium
  • HY-149298

    PSMA Cancer
    PSMA-IN-2 is an inhibitor of PSMA with a Ki value of 1.07 nM. PSMA-IN-2 displays favorable in vivo NIR imaging (λEM = 1088 nm, λex = 808 nm), and can be used for NIRII image-guided tumor resection surgery in PSMA-positive tumor-bearing mice .
    PSMA-IN-2
  • HY-121659

    Others Cancer
    DCFBC is a prostate-specific membrane antigen (PSMA) inhibitor for small animal positron emission tomography (PET) imaging. [18F]DCFBC was prepared by reacting fluorine-18 labeled phenyl bromide with the precursor (S)-2-[3-[(R)-1-carboxy-2-thiolethyl]urea]-glutaric acid in ammonia-saturated methanol at 60°C for 10 min and then purified by C-18 reversed-phase HPLC. [18F]DCFBC was injected via the tail vein in severe combined immunodeficient mice for in vitro biodistribution or imaging. For in vitro biodistribution studies, mice were sacrificed at 5, 15, 30, 60, and 120 min after injection, and tumors, blood, and major organs were collected, weighed, and radioactivity was counted. Imaging was performed using a GE eXploreVista small animal PET scanner, collecting 12 consecutive 10-min frames. Results showed that the radiochemical yield of [18F]DCFBC averaged 16±6% (n=8) from 4-[18F]fluorophenyl bromide. Specific radioactivity ranged from 13 to 133 GBq/Amol (350-3600 Curie/mmol) with an average of 52 GBq/Amol (1392 Curie/mmol; n=6). Biodistribution and imaging studies showed high uptake of [18F]DCFBC in PIP tumors and almost no uptake in FLU tumors. High radiopharmaceutical uptake was also seen in the kidney and bladder; however, radioactivity washout from these organs was faster than from the PIP tumors. Maximum PIP tumor uptake was reached at 60 min post-injection at 8.16±2.55% injected dose/g and decreased to 4.69±0.89 at 120 min post-injection. The PIP tumor-to-muscle ratio was 20 at 120 min post-injection. Based on mouse biodistribution, the dose-limiting organ was the kidney (estimated human absorbed dose: 0.05 mGy/MBq; 0.2 rad/mCi). Conclusions: [18F]DCFBC localizes specifically to PSMA+ expressing tumors in mice and is suitable for small animal PET imaging. This novel radiopharmaceutical is an attractive candidate for further study in PET imaging of prostate cancer.
    DCFBC
  • HY-158125

    PSMA Cancer
    PSMA binder-2 is a ligand for PSMA and can be used to synthesize Ac-PSMA-trillium. Ac-PSMA-trillium is a suitable PSMA-targeting compound with improved PSMA binding properties and pharmacokinetic properties. PSMA ligands have different biological applications after being modified with different radioactive isotopes. If labeled with 111In, it can be used as DOTA chelating agent and imaging agent. Or labeled with 225Ac as a Macropa chelator for targeted radionuclide therapy (TRT) in the study of metastatic castration-resistant prostate cancer (mCRPC) .
    PSMA binder-2
  • HY-149203

    Fluorescent Dye Others
    MQA-P is a multifunctional near-infrared (NIR) fluorescent probe for simultaneously detecting ONOO -, viscosity, and polarity within mitochondria. MQA-P exhibits a remarkable turn-on response to ONOO -em=645 nm) and is highly sensitive to viscosity/polarity in the NIR channel with λem>704 nm. MQA-P exhibits excited-state intramolecular charge transfer (ESICT) feature that is highly polarity-sensitive by engineering N,N-dimethylamino as the electron donor and a quinoline cationic unit as the electron acceptor. MQA-P is used for ferroptosis or cancer diagnosis in vitro and in vivo via dual-channel images .
    MQA-P
  • HY-149203A

    Fluorescent Dye Others
    MQA-P is a multifunctional near-infrared (NIR) fluorescent probe that simultaneously detects ONOO -, viscosity, and polarity within mitochondria. MQA-P exhibits significant response to ONOO -, λem=645 nm; and NIR channel at λem>704 nm Medium is highly sensitive to viscosity/polarity. MQA-P possesses excited-state intramolecular charge transfer (ESICT) properties that are highly sensitive to polarity by designing the N,N-dimethylamino group as the electron donor and the quinoline cation unit as the electron acceptor. MQA-P is used for ferroptosis or cancer diagnosis in vitro and in vivo via dual-channel images .
    MQA-P TFA
  • HY-W087187

    Radionuclide-Drug Conjugates (RDCs) EGFR Cancer
    DOTAGA-anhydride is a DOTA-based metal chelator that can bind to radionuclides and is used to prepare radionuclide drug conjugates (RDCs). DOTAGA-anhydride can be used to label monoclonal antibodies (mAbs) such as trastuzumab (targeting HER2/neu receptor with an affinity of 5.5 nM) under mild conditions (PBS pH 7.4, 25 °C, 30 minutes) after chelation with indium-111. [111In-DOTAGA]-trastuzumab showed a tumor uptake of 65% ID/g in mice bearing breast cancer BT-474 xenografts 72 hours after injection, which is valuable for SPECT/CT imaging and biodistribution studies.
    DOTAGA-anhydride
  • HY-158123

    PSMA Cancer
    PSMA binder-1 is a ligand for PSMA and can be used to synthesize Ac-PSMA-trillium. Ac-PSMA-trillium is a suitable PSMA-targeting compound with improved PSMA binding properties and pharmacokinetic properties. PSMA ligands have different biological applications after being modified with different radioactive isotopes. If labeled with 111In, it can be used as DOTA chelating agent and imaging agent. Or it can be labeled with 225Ac (to obtain Actinium-225-PSMA-Trillium (BAY 3563254)), which has a radioactive killing effect; it can be used as a Macropa chelator for targeted radionuclide therapy (TRT) , has a strong inhibitory effect on metastatic castration-resistant prostate cancer (mCRPC) .
    PSMA binder-1
  • HY-W585442

    Others
    5,9,14,18,23,27,32,36-Octabutoxy-2,3-naphthalocyanine is a photosensitive material with excellent light absorption and electron conduction activity. 5,9,14,18,23,27,32,36-Octabutoxy-2,3-naphthalocyanine is widely used in optoelectronic devices and is considered to be an effective photocatalyst. 5,9,14,18,23,27,32,36-Octabutoxy-2,3-naphthalocyanine can be used to improve the performance of solar cells and increase the photoelectric conversion efficiency. 5,9,14,18,23,27,32,36-Octabutoxy-2,3-naphthalocyanine also has potential anti-tumor activity and can inhibit the proliferation of certain cancer cells. 5,9,14,18,23,27,32,36-Octabutoxy-2,3-naphthalocyanine exhibits excellent fluorescence properties in medical imaging, which helps to improve the clarity and accuracy of imaging. 5,9,14,18,23,27,32,36-Octabutoxy-2,3-naphthalocyanine is studied as a component of a novel compound delivery system to improve the targeting and release effect of the compound.
    5,9,14,18,23,27,32,36-Octabutoxy-2,3-naphthalocyanine

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: